Author

Colm O'Morain

The only good bug is a dead bug
The only good bug is a dead bug

Colm O'Morain

Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report
Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report

Colm O'Morain  et al.

THE IMPACT OF VITAMIN D DEFICIENCY ON COVID-19 INFECTION AND RESPONSE TO VACCINATION
THE IMPACT OF VITAMIN D DEFICIENCY ON COVID-19 INFECTION AND RESPONSE TO VACCINATION

Colm O'Morain  et al.

MYCOBACTERIUM AVIUM PARATUBERCULOSIS INCIDENCE IN PATIENTS WITH CROHN’S DISEASE AND CONTROLS: A SINGLE CENTRE STUDY
MYCOBACTERIUM AVIUM PARATUBERCULOSIS INCIDENCE IN PATIENTS WITH CROHN’S DISEASE AND CONTROLS: A SINGLE CENTRE STUDY

Colm O'Morain  et al.

CLARITHROMYCIN RESISTANCE IS MORE COMMON AMONG LESS VIRULENT HELICOBACTER PYLORI STRAINS - DATA FROM AN IRISH CENTRE
CLARITHROMYCIN RESISTANCE IS MORE COMMON AMONG LESS VIRULENT HELICOBACTER PYLORI STRAINS - DATA FROM AN IRISH CENTRE

Colm O'Morain  et al.

THE IMPACT OF DRUG LEVELS TO ANTI-TNF AND ANTI-INTEGRIN AGENTS ON COVID-19 VACCINE RESPONSE IN PATIENTS WITH IBD
THE IMPACT OF DRUG LEVELS TO ANTI-TNF AND ANTI-INTEGRIN AGENTS ON COVID-19 VACCINE RESPONSE IN PATIENTS WITH IBD

Colm O'Morain  et al.

ASSESSMENT OF FIRST-LINE TREATMENT IN GREECE: DATA FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)
ASSESSMENT OF FIRST-LINE TREATMENT IN GREECE: DATA FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

Colm O'Morain  et al.

REDUCED SEROLOGICAL RESPONSE TO COVID-19 BOOSTER VACCINES IN PATIENTS WITH IBD IS FURTHER DIMINISHED BY TNF INHIBITOR THERAPY; VARIATION STUDY PART 2 (VARIABILITY INRESPONSEIN IBDAGAINSTSARS-COV-2IMMUNISATION)
REDUCED SEROLOGICAL RESPONSE TO COVID-19 BOOSTER VACCINES IN PATIENTS WITH IBD IS FURTHER DIMINISHED BY TNF INHIBITOR THERAPY; VARIATION STUDY PART 2 (VARIABILITY INRESPONSEIN IBDAGAINSTSARS-COV-2IMMUNISATION)

Colm O'Morain  et al.

European Crohn’s and Colitis Organisation Topical Review on Environmental Factors in IBD
European Crohn’s and Colitis Organisation Topical Review on Environmental Factors in IBD

Colm O'Morain  et al.

REAL-WORLD COMPARATIVE EFFECTS OF THREE-IN-ONE SINGLE CAPSULE BISMUTH QUADRUPLE THERAPY VS. NON-BISMUTH QUADRUPLE CONCOMITANT THERAPY: INTERIM ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
REAL-WORLD COMPARATIVE EFFECTS OF THREE-IN-ONE SINGLE CAPSULE BISMUTH QUADRUPLE THERAPY VS. NON-BISMUTH QUADRUPLE CONCOMITANT THERAPY: INTERIM ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Colm O'Morain  et al.

SAFETY OF THE TREATMENT OF H. PYLORI INFECTION: EXPERIENCE FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG) ON 22,000 PATIENTS
SAFETY OF THE TREATMENT OF H. PYLORI INFECTION: EXPERIENCE FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG) ON 22,000 PATIENTS

Colm O'Morain  et al.

BISMUTH QUADRUPLE THREE-IN-ONE SINGLE CAPSULE: 3 OR 4 TIMES DAILY? SUB-ANALYSIS OF THE SPANISH DATA OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
BISMUTH QUADRUPLE THREE-IN-ONE SINGLE CAPSULE: 3 OR 4 TIMES DAILY? SUB-ANALYSIS OF THE SPANISH DATA OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Colm O'Morain  et al.

EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): ANALYSIS OF EMPIRICAL SECOND-LINE TREATMENTS IN EUROPE
EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): ANALYSIS OF EMPIRICAL SECOND-LINE TREATMENTS IN EUROPE

Colm O'Morain  et al.

ROOM FOR IMPROVEMENT IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION: LESSONS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
ROOM FOR IMPROVEMENT IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION: LESSONS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Colm O'Morain  et al.

EXPERIENCE WITH RIFABUTIN-CONTAINING THERAPY IN 426 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EXPERIENCE WITH RIFABUTIN-CONTAINING THERAPY IN 426 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Colm O'Morain  et al.

BISMUTH QUADRUPLE THREE-IN-ONE SINGLE CAPSULE: 3 OR 4 TIMES DAILY? SUB-ANALYSIS OF THE SPANISH DATA OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
BISMUTH QUADRUPLE THREE-IN-ONE SINGLE CAPSULE: 3 OR 4 TIMES DAILY? SUB-ANALYSIS OF THE SPANISH DATA OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Colm O'Morain  et al.

EFFECTIVENESS OF FIRST-LINE H. PYLORI ERADICATION THERAPY ACCORDING TO THE DAILY STATIN-USE: ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EFFECTIVENESS OF FIRST-LINE H. PYLORI ERADICATION THERAPY ACCORDING TO THE DAILY STATIN-USE: ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Colm O'Morain  et al.

BISMUTH QUADRUPLE REGIMEN WITH TETRACYCLINE OR DOXYCYCLINE VERSUS PYLERA® AS THIRD-LINE RESCUE THERAPY FOR H. PYLORI INFECTION: A PROSPECTIVE MULTICENTER ANALYSIS OF THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)
BISMUTH QUADRUPLE REGIMEN WITH TETRACYCLINE OR DOXYCYCLINE VERSUS PYLERA® AS THIRD-LINE RESCUE THERAPY FOR H. PYLORI INFECTION: A PROSPECTIVE MULTICENTER ANALYSIS OF THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

Colm O'Morain  et al.

EFFECTIVENESS OF TREATMENTS AGAINST HELICOBACTER PYLORI ACCORDING TO RESISTANCE TO CLARITHROMYCIN: DATA FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)
EFFECTIVENESS OF TREATMENTS AGAINST HELICOBACTER PYLORI ACCORDING TO RESISTANCE TO CLARITHROMYCIN: DATA FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

Colm O'Morain  et al.

HELICOBACTER PYLORI ANTIBIOTIC RESISTANCE: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
HELICOBACTER PYLORI ANTIBIOTIC RESISTANCE: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Colm O'Morain  et al.

Item 1 - 20 / 31
1
2